Developmental toxicity study of lersivirine in mice.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Birth defects research. Part B. Developmental and reproductice toxicology

• Publication date

  2012-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/bdrb.21008PMID 22447726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development.

  2012cited by this paper
• Antiretroviral use during pregnancy for treatment or prophylaxis

  2011cited by this paper
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

  2010cited by this paper
• Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

  2010cited by this paper
• Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.

  2010cited by this paper
• Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations

  2009cited by this paper
• Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

  2008cited by this paper
• Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.

  2008cited by this paper
• Efavirenz reclassified as FDA pregnancy category D.

  2005cited by this paper
• Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy.

  2003cited by this paper
• Terminology of developmental abnormalities in common laboratory mammals (version 1).

  1997cited by this paper
• REFINEMENTS IN RAPID CLEARING TECHNIC IN THE KOH-ALIZARIN RED S METHOD FOR FETAL BONE.

  1964cited by this paper
• REFINEMENTS IN RAPID CLEARING TECHNIC IN THE KOH-ALIZARIN RED S METHOD FOR FETAL BONE.

  1964cited by this paper
• New tables for multiple comparisons with a control.

  1964cited by this paper
• Multiple Comparisons Using Rank Sums

  1964cited by this paper
• An Effect of the Uterine Environment upon Skeletal Morphology in the Mouse

  1958cited by this paper
• Genetical studies on the skeleton of the mouse XXI. The girdles and the long limb bones

  1957cited by this paper
• A Multiple Comparison Procedure for Comparing Several Treatments with a Control

  1955cited by this paper
• Genetical studies on the skeleton of the mouse xv. Relations between major and minor variants

  1955cited by this paper

• Reproductive and developmental toxicity assessments of LPM3480392, a novel mu opioid receptor biased agonist in rats.

  2023cites this paper
• Adult mice expressing a Braf Q241R mutation on an ICR/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype.

  2015cites this paper
• Lersivirine – a new drug for HIV infection therapy

  2013cites this paper